Data and analysis support for vaccine immune response work
Core E Data Management Core
This effort organizes and analyzes blood and tissue immune measurements from people vaccinated against or infected by COVID‑19, flu, or dengue.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11481646 on NIH RePORTER |
What this research studies
From your viewpoint, researchers will collect blood and sometimes tissue samples from people who were vaccinated or who had these infections. They will measure genes, antibodies, and immune signaling molecules in bulk samples and then use advanced single-cell and spatial methods to look at individual immune cells. A central data core will clean, store, and run the computational analyses to combine these measurements across studies. The core also helps choose which samples need deeper single-cell profiling and integrates results to reveal how immune responses differ between people and vaccines.
Who could benefit from this research
Good fit: Ideal participants are people who have been vaccinated against or infected by SARS‑CoV‑2 (COVID‑19), influenza, or dengue and who can donate blood or relevant tissue samples.
Not a fit: People without exposure or vaccination to these viruses or those seeking immediate clinical treatment are unlikely to receive direct medical benefits from participating.
Why it matters
Potential benefit: If successful, this work could reveal how different people’s immune systems respond to vaccines and infections, helping design better or more tailored vaccines.
How similar studies have performed: High-throughput antibody, gene-expression, and single-cell profiling have already produced useful vaccine and infection insights, though combining these approaches across COVID‑19, flu, and dengue is relatively new.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Van Bakel, Harm — Icahn School of Medicine at Mount Sinai
- Study coordinator: Van Bakel, Harm
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.